Coverage of FDA warnings regarding the risks of obtaining popular glucagon-like peptide-1 (GLP-1) receptor agonist drugs such as semaglutide and tirzepatide from compounding pharmacies quotes ISMP staff and provides ISMP safe practice recommendations.
For the full text, visit Specialty Pharmacy Continuum online. Please note that access may require free registration.
